Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Tech Dows on Jan 31st, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $11.18, for a total value of $22,360.00. Following the completion of the transaction, the president now owns 2,897,138 shares of the company’s stock, valued at $32,390,002.84. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Songjiang Ma also recently made the following trade(s):

On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $11.50 on Friday. The company’s 50-day moving average price is $11.09 and its 200-day moving average price is $12.56. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $26.37.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GYRE. FMR LLC bought a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at approximately $47,000. Barclays PLC raised its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the period. State Street Corp lifted its position in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. Rhumbline Advisers purchased a new position in Gyre Therapeutics during the second quarter worth $123,000. Finally, Renaissance Technologies LLC purchased a new position in Gyre Therapeutics during the second quarter worth $166,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.